Analytical Data
-
Gene name
CD42a/GP9
- Application
-
Alternative Names
CD42-A; CD42a; GPIX; Glycoprotein 9
-
Species
Rat
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q4AEG0
-
Expression Region
Met1~Asn189
-
Molecular Weight
51kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD42a, also known as glycoprotein IX (GP9), is a key component of the multimeric glycoprotein complex known as the platelet glycoprotein VI (GPVI) receptor, which plays an essential role in thrombus formation and stability. This study of CD42a/GP9 recombinant proteins is driven by the need to understand their specific interactions and functionalities in platelet activation and aggregation processes. Abnormalities in GP9 expression or function can lead to various bleeding disorders, making it a critical target for therapeutic interventions. Research on recombinant CD42a/GP9 proteins has advanced significantly due to their potential implications in the development of new antithrombotic therapies that aim to modulate platelet function without the extensive side effects associated with traditional anticoagulants. Furthermore, understanding the structural properties and binding mechanisms of CD42a/GP9 can facilitate the design of novel biomaterials for medical applications, including biosensors and drug delivery systems. Overall, the exploration of CD42a/GP9 recombinant proteins is vital for further elucidating the molecular mechanisms underlying platelet physiology and for the development of targeted treatments for thrombotic diseases.
